NCT05361382Active, not recruitingPhase 1
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 822 (actual)
- First submitted
- 29 Apr 2022
- Start date
- 2 Mar 2022
- Primary completion date
- 31 May 2027
- Lead sponsor
- Tharick Pascoal
- Diseases
- Alzheimer disease
- NCT number
- NCT05361382
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 822
- From 2 Mar 2022 to the primary completion date, 31 May 2027
- 9 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have any condition or are taking any medication that could increase the risk to the participant, limit the ability to tolerate or interfere with the results of the tests and procedures (in the opinion of the investigator).
Other
- Inability to provide informed consent by self or by proxy.
- Pregnant or breastfeeding women.
Who the study is looking for
- Have a study partner who will be able to provide an independent evaluation of functioning.
- Willing and capable of undergoing repeated MR/PET imaging.
- Fluent in a language approved by the coordinating center.
- At screening, must have no cognitive impairment, or meet criteria for single- or multiple-domain amnestic mild cognitive impairment or Alzheimer's disease dementia.
Age in the registry: 18 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (9)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McGill University Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| Sant Pau Biomedical Research Institute Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Lawrence Berkeley National Laboratory Coordinator of this site? Confirm its status | Berkeley | United States | Unknown status |
| Houston Methodist Neurological Institute Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| University of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
| Brown University Coordinator of this site? Confirm its status | Providence | United States | Unknown status |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
| Washington University in St. Louis Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.